{
  "docId": "019de071-3fcc-709d-bd81-493d670a1b54",
  "docSlug": "75c0ef2784bf914c01a48398bea9ca14",
  "documentTitle": "Caribou Biosciences | IPO Presentation Deck | 44 slides",
  "authorId": "caribou-biosciences",
  "authorName": "Caribou Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7744917,
  "pageNumber": 24,
  "pageCount": 44,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide outlines a standard 3+3 dose escalation clinical trial design.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-3fcc-709d-bd81-493d670a1b54/24",
  "deckHref": "/decks/019de071-3fcc-709d-bd81-493d670a1b54",
  "deckJsonHref": "/decks/019de071-3fcc-709d-bd81-493d670a1b54.json",
  "deckAnchorHref": "/decks/019de071-3fcc-709d-bd81-493d670a1b54#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Clinical trial flow from patient enrollment to Part A (dose escalation) and Part B (expansion).",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a8f29c1-49ad-461c-b302-319ac32d1457",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "CB-010 lymphodepletion (cy/flu combo) uses a more intensive regimen than other allo CAR-Ts, enabling improved engraftment and potentially enhanced efficacy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c25c491-c68d-4b63-a5e9-27bd1ed6d04d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "CB-010 ANTLER Phase 1 open-label clinical trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87153812-ec73-4639-9db1-cc405da5d878",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "3+3 dose escalation",
      "slug": null,
      "matchId": "42ccd9c5-99e7-486d-9ca1-bfaa9dd6834c",
      "evidence": "Explicitly mentioned in the diagram",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 36,
      "from": 15,
      "beatId": "06e1eeef-f9ed-48e8-9be8-6ff4bbd93b58",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Traction is presented on pages 15-36",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}